germanium and Adenocarcinoma

germanium has been researched along with Adenocarcinoma* in 7 studies

Other Studies

7 other study(ies) available for germanium and Adenocarcinoma

ArticleYear
Effect of germanium, poly-trans-[2-carboxyethyl] germasesquioxane on natural killer (NK) activity in dogs.
    The Journal of veterinary medical science, 2002, Volume: 64, Issue:8

    In an attempt to study the immunological effects on normal and adenocarcinoma (AC) dogs, the natural killer (NK) activity was determined. Augmentation of NK cell activities in responsive normal and AC dogs that indicatedanergy in the phaseolus vulgaris agglutinin (PHA) skin-test was manifested when the animals were accordingly treated with germanium (GN).

    Topics: Adenocarcinoma; Administration, Oral; Animals; Cytotoxicity Tests, Immunologic; Dog Diseases; Dogs; Germanium; Killer Cells, Natural; Male; Radioisotopes

2002
Effect of germanium on 1,2-dimethylhydrazine-induced intestinal cancer in rats.
    Diseases of the colon and rectum, 1990, Volume: 33, Issue:2

    Through recent research, the trace element, germanium, was found to have an anticancer effect. The purpose of this research was to determine the effect of germanium on 1,2-dimethylhydrazine-induced intestinal cancer in rats. Ninety-six 8-week-old Sprague-Dawley male rats were divided into 4 groups, with 24 rats in each group. All received dimethylhydrazine, 20 mg/kg body weight, subcutaneously, once a week for 20 weeks. Except for one control group, the other three groups were subdivided into six groups and administered three different kinds of germanium (inorganic germanium, organic germanium, and natural organic germanium) one month before and during dimethylhydrazine treatment, and during dimethylhydrazine treatment, respectively. Twenty-four weeks after carcinogen exposure, all surviving animals were sacrificed and examined for intestinal tumors. The number and location of the tumors were recorded and the pathology examined. The incidence of intestinal cancer in the control group (dimethylhydrazine only) was 91 percent; in groups provided with inorganic germanium one month before and during dimethylhydrazine treatment, and during dimethylhydrazine treatment only, it was 91 and 78 percent; in groups provided with organic germanium one month before and during dimethylhydrazine treatment, and during dimethylhydrazine treatment only, it was 64 and 64 percent; in groups provided with natural organic germanium one month before and during dimethylhydrazine treatment and during dimethylhydrazine treatment only, it was 50 and 45 percent. From these results, the authors conclude that natural organic germanium has the best prevention effect for intestinal cancer in this animal model (P less than 0.01), followed by organic germanium (P less than 0.05). Inorganic germanium has no effect. However, there is no difference in the cancer prevention effect of germanium provided one month before and during dimethylhydrazine treatment, and during dimethylhydrazine treatment only.

    Topics: 1,2-Dimethylhydrazine; Adenocarcinoma; Adenocarcinoma, Mucinous; Animals; Carcinogens; Dimethylhydrazines; Germanium; Intestinal Neoplasms; Male; Rats; Rats, Inbred Strains

1990
Phase II study of spirogermanium in advanced (extensive) non-small cell lung cancer.
    Cancer treatment reports, 1986, Volume: 70, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Evaluation; Female; Germanium; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Spiro Compounds

1986
Phase II trial of spirogermanium in advanced renal cell carcinoma: a Cancer and Leukemia Group B study.
    Cancer treatment reports, 1984, Volume: 68, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Germanium; Humans; Kidney Neoplasms; Male; Middle Aged; Organometallic Compounds; Spiro Compounds

1984
[Effects of interferon and its inducers on neutrophil chemiluminescence].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:7

    In order to evaluate effects of interferon (IFN) and its inducers on neutrophil functions, neutrophil chemiluminescence (ChL) was assayed in 12 patients treated with IFN (human lymphoblastoid interferon, 3.0 X 10(6) units/day i.m. daily) or Ge-132 (2,250 mg/day p.o. daily). The peak levels of neutrophil ChL, assayed one week after the initiation of treatment, were increased in comparison to those before treatment, but one month after treatment they were decreased to pretreatment levels in spite of the daily administration of the agent. On the basis of these results, it was concluded that IFN and Ge-132 enhanced the host defence mechanism including the activation of neutrophils, which appeared at the early phase of the host reaction.

    Topics: Adenocarcinoma; Adult; Aged; Female; Germanium; Humans; Interferon Inducers; Interferon Type I; Kidney Neoplasms; Leukemia, Myeloid; Luminescent Measurements; Lymphoma; Male; Middle Aged; Multiple Myeloma; Neutrophils; Organometallic Compounds; Oxygen Consumption; Phagocytosis; Propionates

1984
The effects of chemotherapy on bony metastases as measured by quantitative skeletal imaging.
    Clinical nuclear medicine, 1983, Volume: 8, Issue:1

    The effect of chemotherapy on bony metastases from adenocarcinoma of the colon was investigated by quantitative skeletal imaging over a two-month interval. The quantitative skeletal imaging results correlated with conventional blood chemistry results over this time period. While chemical assay techniques furnish an average value of lesion response, the quantitative bone scan represents a method for individual lesion analysis. This methodology has the potential to provide a better understanding of metastatic bone disease therapy.

    Topics: Adenocarcinoma; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Colonic Neoplasms; Diphosphonates; Fluorouracil; Germanium; Humans; Male; Middle Aged; Organometallic Compounds; Radionuclide Imaging; Spiro Compounds; Technetium; Technetium Compounds; Time Factors

1983
Phase II trial of spirogermanium in breast adenocarcinoma: a Cancer and Leukemia Group B Study.
    Cancer treatment reports, 1982, Volume: 66, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Germanium; Humans; Middle Aged; Organometallic Compounds; Spiro Compounds

1982